Compare The Coca-Cola Co K (KO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs TG Therapeutics Inc — how do they compare? The Coca-Cola Co K trades at $86.74 (market cap $372.08B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: The Coca-Cola Co K is far larger — about 48.7× TG Therapeutics Inc's market cap, and The Coca-Cola Co K pays a 2.45% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KO | TGTX | |
|---|---|---|
Market Cap | $372.08B | $7.64B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $89.08 | $59.06 |
52-Week Low | $65.67 | $26.94 |
Enterprise Value | $399.26B | $7.84B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $86.67, down 0.23% on the day, with a bullish technical signal driven by moving averages and strong support at $85. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.97 exceeding expectations, and maintains high profitability margins, including a 28.56% net income margin. Recent news highlights institutional buying and stable demand trends, while the upcoming Q3 2026 earnings are anticipated at $0.87 EPS.
The stock offers a compelling dividend yield with 64 consecutive years of increases, supported by solid cash flow and a consensus price target of $95.83 implying 10.6% upside. Risks include regional demand volatility in Asia and high debt levels, but analyst sentiment is bullish with 60% buy ratings. Long-term growth prospects remain intact given brand strength and global footprint.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
